Anne Fortier, VP of Drug Discovery and Development at Conscience. Anne is a seasoned drug hunter with a PhD in Biochemistry from McGill University and a track record of delivering first-in-class small-molecule therapies, including inaxaplin, through senior roles at Vertex Pharmaceuticals. She leads Conscience’s Developing Medicines through Open Science program, which supports collaborative drug discovery in areas where market solutions are limited, such as orphan diseases and antimicrobial resistance.